Litcius/Paper detail

Efficacy of anifrolumab across organ domains in patients with moderate-to-severe systemic lupus erythematosus: a post-hoc analysis of pooled data from the TULIP-1 and TULIP-2 trials

Eric F. Morand, Richard Furie, Ian N Bruce, Edward M Vital, Maria Dall’Era, Emmanuelle Maho, Lilia Pineda, Raj Tummala

2022The Lancet Rheumatology114 citationsDOI

Topics & Concepts

MedicineInternal medicineMucocutaneous zonePost-hoc analysisPlaceboSystemic lupus erythematosusSerologyBelimumabLupus erythematosusImmunologyDiseaseAntibodyPathologyB-cell activating factorAlternative medicineB cellSystemic Lupus Erythematosus ResearchRheumatoid Arthritis Research and TherapiesSpondyloarthritis Studies and Treatments
Efficacy of anifrolumab across organ domains in patients with moderate-to-severe systemic lupus erythematosus: a post-hoc analysis of pooled data from the TULIP-1 and TULIP-2 trials | Litcius